the peripheral blood is treated with 8-methoxypsoralen, which is then activated with UV
light. ECP is currently a standard therapy for cutaneous T-cell lymphoma (CTCL) and is also
effective for graft-versus-host disease (GVHD). The investigators would like to study the
outcomes (response rates) of patients receiving ECP treatment and other factors relating to
their disease and treatment, as well as procedural events, such as complications.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
- Cancer Help Line: (800) 639-6918
- Email: email@example.com
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.